Quantcast

Latest Organofluorides Stories

2014-08-11 12:26:57

Significant Opportunity Exists for New Therapies to Treat GIST, Particularly those for Treating Unresectable and/or Metastatic Disease in Later-Line Settings BURLINGTON, Mass., Aug. 11, 2014 /PRNewswire/ -- Decision Resources Group finds that the treatment landscape of gastrointestinal stromal tumors (GIST) will not change dramatically through 2023 as no new therapies are expected to launch for this indication. Treatment of GIST is largely dependent on tumor size, location and growth rate and...

2014-08-11 08:28:44

PITTSBURGH, Aug. 11, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has launched Capecitabine Tablets USP, 150 mg and 500 mg, the generic version of Genentech's Xeloda® Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated as monotherapy, adjuvant therapy and combination therapy for certain types of breast, colon and colorectal cancers.(1) CEO...

2014-08-11 08:28:42

LONDON, August 11, 2014 /PRNewswire/ -- Avillion LLP, a co-developer of late-stage pharmaceutical assets, announces that the first patients have been dosed in the United States in a global Phase 3 clinical trial called "BFORE," which is designed to assess the effectiveness and safety of BOSULIF(R) (bosutinib) as a first-line treatment for patients with chronic phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML). The first patient was dosed on July...

2014-08-08 23:01:07

The Firm is representing Risperdal lawsuit clients who allegedly developed gynecomastia, or male breast growth, due to the use of the antipsychotic medication. New York, New York (PRWEB) August 08, 2014 As Risperdal lawsuits (http://www.lawreward.com/risperdal/) mount in U.S. courts, Bernstein Liebhard LLP notes that yet another group of researchers has found data to support a link between exposure to risperidone, the active ingredient in the atypical antipsychotic drug, and the...

2014-08-05 08:33:58

POINT ROBERTS, Wash. and NEW YORK, Aug. 5, 2014 /PRNewswire/ -- Investorideas.com, a global news source covering leading sectors including biotech, issues an exclusive Q&A interview with Dr. Craig Dionne, PhD, GenSpera's (OTCQB: GNSZ) CEO. Dr. Dionne discusses the company's lead drug G-202 and how they have taken a powerful toxin named thapsigargin to selectively target and kill cancer cells. He also shares insight into the key points that make them different from competitive...

2014-08-02 23:01:40

The Firm is representing a number of Risperdal lawsuit clients who allegedly developed gynecomastia, or male breast growth, due to their use of the atypical antipsychotic drug. New York, New York (PRWEB) August 02, 2014 Risperdal lawsuits (http://www.lawreward.com/risperdal-lawsuit/) that allege use of the antipsychotic medication caused men and boys to develop gynecomastia, or male breast growth, continue to mount in U.S. courts, Bernstein Liebhard LLP reports. According to court...

2014-07-31 12:28:49

Delivering novel fluorination tools for drug and material development SAN FRANCISCO, July 31, 2014 /PRNewswire/ -- Catylix, Inc. (Burbank, California) and Aspira Scientific (Milpitas, California) announced today the formation of a joint venture to develop and commercialize new fluorination products and related chemistry. Developing improved biologically active molecules has benefited from the use of substituents that are chemically stable, resistant to metabolism, and combine...

2014-07-30 08:33:01

Primary efficacy endpoints met in all nine new trials of investigational PCSK9 inhibitor TARRYTOWN, N.Y. and PARIS, July 30, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that nine new Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia met their primary efficacy endpoint of a greater percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to placebo...

2014-07-30 08:32:55

- Primary efficacy endpoints met in all nine new trials of investigational PCSK9 inhibitor - PARIS and TARRYTOWN, N.Y., July 30, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that nine new Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia met their primary efficacy endpoint of a greater percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to...

2014-07-28 04:21:34

HILDEN, Germany and LONDON, July 28, 2014 /PRNewswire/ -- - Collaboration aims to create and commercialize companion diagnostic using genomic data from plasma samples to guide the use of IRESSA for non-small cell lung cancer patients - New blood test will build on QIAGEN's FDA-approved therascreen EGFR test and is planned to run on Rotor-Gene Q, member of the QIAsymphony family of automated instruments -...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related